肝硬化放腹水后应用右旋糖酐治疗顽固性腹水临床研究  

Clinical Study on the Treatment of Obstinate Hepatocirrhosis Ascites by Dextran After Paracentesis

作　　者：陈亚利[1] 叶晓敏[1] 李建萍[1] 

机构地区：[1]西昌市人民医院内一科内二科,四川西昌615000

出　　处：《华西医学》2009年第3期651-654,共4页West China Medical Journal

摘　　要：目的:为了探讨肝硬化放腹水后应用右旋糖酐40代替人血白蛋白治疗顽固性腹水的临床疗效及其经济性。方法:将216例肝硬化顽固性腹水患者随机分为A,B,C三组。A组:定期放腹水后应用右旋糖酐40;B组:定期放腹水后应用人血白蛋白或血浆;C组:传统治疗方法,限钠和不断增加利尿剂用量。结果:A组分别与B组,C组相比较,其腹水消退时间,ALT复常率,输血不良反应,住院费用,平均住院日,好转治愈率,死亡率,以上各项对比均有显著性差异(P<0.05)。血清蛋白量的对比无显著性差异(P>0.05)。结论:肝硬化放腹水后应用右旋糖酐40治疗顽固性腹水,能缩短病程,减少住院日,降低医疗费用,降低死亡率。Objective：To explore the clinical effect and economics on the treatment of obstinate hepatocirrhosis ascites by dextran instead of albumin. Methods：The 216 patients of obstinate hepatocirrhosis ascites were divided into three groups randomly. Group A were treated with dextran regularly after paracentesis40. Group B were treated with albumin or plasma. Group C were treated with restricting natrium and increasing the dosage of diuretic. Results： Comparison with group B and C, the rate of adverse transfusion reaction, hospitalization expenses and average stay in hospital, cure and mortality rate are significant difference（P〈0.05）, the dosage of albumin is no significant difference（P〉0.05）in Group A. Conclusion： The patients treated with dextran after paracentesis40 can shorten the course of disease and period of hospitalization,reduce the therapy cost and mortality rate.

关 键 词：肝硬化顽固性腹水 放腹水 右旋糖酐40 人血白蛋白 代替 

分 类 号：R575.2[医药卫生—消化系统]